¹Ú°æÂù¼¾ÅÍÀå
´ã´ç¾÷¹«
¾Ï °ü·Ã À¯ÀüÀÚÀÇ ´ë±Ô¸ð °Ë»ö ¹× ¹ß±¼
Ä¡·áÁ¦ °³¹ßÀ» À§ÇÑ Èĺ¸ Ÿ°Ù À¯ÀüÀÚÀÇ ±â´É¼º °ËÁõ
¸ñÇ¥
ºòµ¥ÀÌÅÍ/AI ºÐ¼® ±â¹Ý ¾Ï Á¤¹ÐÄ¡·á±â¼ú °³¹ß
Genome-wide À¯ÀüÀÚ Á¦¾î±â¼úÀ» ÀÌ¿ëÇÑ ¾Ï ¸ÂÃãÄ¡·á±â¼ú °³¹ß
¾Ï¼¼Æ÷ ÀÌÁú¼º ºÐ¼® ±â¹Ý ¾Ï ¸ÂÃãÄ¡·á±â¼ú °³¹ß
¿¬±¸ºÐ¾ß
Genome-wide À¯ÀüÀÚ ¹ßÇö Á¦¾î±â¼úÀ» ÀÌ¿ëÇÑ ¸ÂÃãÀÇ·á ±â¼ú °³¹ß
Genome-wide shRNA ±â¹Ý ¾Ï Ä¡·áÇ¥Àû À¯ÀüÀÚ ¹ß±¼ ¹× Ä¡·á±â¼ú °³¹ß
Æó¾Ï/°£¾ÏÀÇ Ç¥ÀûÄ¡·áÁ¦(Gefitinib/Sorafenib) ³»¼ºÀ¯µµ À¯ÀüÀÚ ¹ß±¼ ¹× Ä¡·á±â¼ú °³¹ß
À§¾ÏÀÇ ³Ä¡¼º ºÐÀÚ¾ÆÇü¿¡ ´ëÇÑ Ä¡·áŸ°Ù ¹ß±¼ ¹× °ËÁõ
Genome-wide CRISPR ½Ã½ºÅÛ ±â¹Ý ¾Ï Ä¡·áÇ¥Àû À¯ÀüÀÚ ¹ß±¼ ¹× Ä¡·á±â¼ú °³¹ß
CRISPR À¯ÀüÀÚ ¹ßÇöÃËÁø ½Ã½ºÅÛ ±â¹Ý ¾Ï Ä¡·áÇ¥Àû À¯ÀüÀÚ ¹ß±¼ ¹× Ä¡·á±â¼ú °³¹ß
Hypoxia µî ¾Ï ¹Ì¼¼È¯°æ(tumor microenvironment) Á¶Àý°ü·Ã ±â´É¼º À¯ÀüÀÚ ¹ß±¼ ¹× Ä¡·á±â¼ú °³¹ß
ÈļºÀ¯Àüü ºÐ¼® ±â¼úÀ» ÀÌ¿ëÇÑ ¼¼Æ÷ºÐÈ ¿¬±¸ ¹× ¼¼Æ÷ºÐÈÁ¦¾î±â¼ú °³¹ß
´ÜÀϼ¼Æ÷ DNA ¸ÞÆ¿È, Å©·Î¸¶Æ¾ ±¸Á¶ ºÐ¼® ¹× ´Ù¾çÇÑ È÷½ºÅæ º¯Çü ºÐ¼® ±â¼ú È®¸³
´Ù¾çÇÑ ÈļºÀ¯Àüü Á¤º¸ ºÐ¼® ÆÄÀÌÇÁ¶óÀÎ ±¸Ãà ¹× ºÐ¼® ¼ÒÇÁÆ®¿þ¾î °³¹ß
ÈļºÀ¯Àüü ºÐ¼® ±â¹Ý ¼¼Æ÷ºÐÈ Á¦¾î±â¼ú °³¹ß
Áٱ⼼Æ÷ÀÇ ºÐÈ °úÁ¤¿¡¼ DNA methylome, Histone modification, transcriptome º¯È¸¦ ºñ±³ ºÐ¼®ÇÏ¿© ÈļºÀ¯ÀüÀÎÀÚ »óÈ£°£ÀÇ ³×Æ®¿öÅ©¿¬±¸
Áٱ⼼Æ÷ ºÐÈÀÇ ¸ð´ÏÅ͸µÀ» À§ÇÑ ¹ÙÀÌ¿À¸¶Ä¿ °³¹ß
NGS¸¦ ÀÌ¿ëÇÑ Ç¥ÀûÄ¡·áÁ¦ ³»¼º ȹµæ ¾Ï¼¼Æ÷ÀÇ Transcriptome, DNA methylome, Histone modification ÅëÇÕ ºÐ¼®
Ç×¾ÏÁ¦ ³»¼ºÀÇ ÁöÇ¥°¡ µÇ´Â epimutation µ¿Á¤
Genome-wide functional screening (shRNA, CRISPR-Cas9)À» À§ÇÑ »ý¹°Á¤º¸ ºÐ¼® ½Ã½ºÅÛ ±¸Ãà
Genome-wide shRNA ȤÀº CRISPR-Cas9¿Í NGS¸¦ °áÇÕÇÑ barcode-seq µ¥ÀÌÅÍ ºÐ¼®À» À§ÇÑ ºÐ¼® °úÁ¤ ¹× ¼ÒÇÁÆ®¿þ¾î °³¹ß
´Ù¾çÇÑ genome-wide screening µ¥ÀÌÅÍÀÇ ¼öÁý, ºÐ¼® ¹× ÅëÇÕÀ» ÅëÇÑ functional screening µ¥ÀÌÅͺ£À̽º ¹× Ȱ¿ë ½Ã½ºÅÛ ±¸Ãà
¿¬±¸¼º°ú
Á¥»ê½ÅÈ£ Á¶Àý ½Å±Ô ¾Ï À¯ÀüÀÚ ¹ß±¼
ÇǷι°Áú·Î ¾Ë·ÁÁ³´ø Á¥»ê(Lactate)ÀÌ ¼¼Æ÷¼ºÀå ¹× Ç÷°ü»ý¼ºÀ» Á¶ÀýÇÏ´Â Áß¿äÇÑ ½ÅÈ£¹°Áú·Î½á ÀÛ¿ëÇÔÀ» ±Ô¸í
»õ·ÎÀÌ ¹ß±¼µÈ Á¥»ê½ÅÈ£ Á¶Àý À¯ÀüÀÚ NDRG3ÀÇ Á¶ÀýÀ» ÅëÇØ ¾Ï¼¼Æ÷ÀÇ ´ë»ç°úÁ¤°ú ½ÅÈ£Àü´Þü°è¸¦ µ¿½Ã¿¡ Ç¥ÀûÀ¸·Î ÇÏ´Â È¿À²ÀûÀÎ ¾Ï Ä¡·áÁ¦ ¹× ¿°Áõ Áúȯ Ä¡·áÁ¦ °³¹ß °¡´É¼º Á¦½Ã
½Å±Ô Ç׾Ϲ°Áú °³¹ß
¾Ï ¼¼Æ÷ÀÇ Áõ½ÄÀ» ¾ïÁ¦ÇÏ´Â °ÍÀ¸·Î ¾Ë·ÁÁø¡®RhoB¡¯¸¦ Ÿ°ÙÀ¸·Î ÇÏ´Â ÀúºÐÀÚ ÈÇÕ¹°À» ÇÕ¼º, À̸¦ À§¾Ï, Àü¸³¼±¾Ï¿¡ °É¸° »ýÁã¿¡ Åõ¿©ÇÑ °á°ú ¾Ï ¼¼Æ÷ÀÇ Áõ½ÄÀÌ ÇöÀúÈ÷ ¾ïÁ¦µÉ »Ó¸¸ ¾Æ´Ï¶ó ±âÁ¸ Ç×¾ÏÁ¦ Åõ¿©½Ã °üÂûµÇ´Â üÁß °¨¼Ò ºÎÀÛ¿ëÀÌ °³¼±µÇ´Â °ÍÀ» È®ÀÎ
¾Ï ¼¼Æ÷´Â Á¤»ó¼¼Æ÷¿Í ºñ±³ÇÏ¿© ¸Å¿ì ½ÉÇÑ proteotoxic stress »óȲ¿¡ ³ëÃâµÇ¾î ÀÖÀ¸¸ç, ¾Ï¼¼Æ÷´Â »ýÁ¸/Áõ½ÄÀ» À§ÇØ HSF1 Ȱ¼ºÈ¸¦ ÅëÇØ molecular chaperonesÀ» °ú¹ßÇöÇÑ´Ù (non-oncogene addicition). ¡®HSF1¡¯À» Ÿ°ÙÀ¸·Î ÇÏ´Â ÀúºÐÀÚ ÈÇÕ¹°µé(KRIBB11, cantharidin, fisetin)À» ÇÕ¼º/ºÐ¸®, À̸¦ ´ëÀå¾Ï¿¡ °É¸° »ýÁã¿¡ Åõ¿©ÇÑ °á°ú ¾Ï ¼¼Æ÷ÀÇ Áõ½ÄÀÌ ÇöÀúÈ÷ ¾ïÁ¦µÉ »Ó¸¸ ¾Æ´Ï¶ó µ¶¼º Ç×¾ÏÁ¦ Åõ¿©½Ã ¾ß±âµÇ´Â üÁß °¨¼Òµµ ³ªÅ¸³ªÁö ¾ÊÀ½
Ç×¾ÏÈ¿°ú¸¦ µ¿¹°½ÇÇèÀ» ÅëÇØ ÀÔÁõÇϰí, Ç×¾Ï È¿°ú°¡ ¿ì¼öÇÏ°í µ¶¼º Ãø¸é ¿¡¼µµ ¾ÈÀüÇÏ¿© ½Å±Ô Ç×¾ÏÁ¦ °³¹ß ºÐ¾ß¿¡¼ ±¹Á¦°æÀï·Â È®º¸
½Å±Ô Ç׾Ϲ°Áú LW6ÀÇ Ç¥Àû ´Ü¹éÁú ¹ß±¼ ¹× ÀÛ¿ë±âÀü ±Ô¸í
HIF-1 ÀúÇØ Ȱ¼ºÀ» °¡Áø LW6ÀÇ ÄɹÌÄÃÇÁ·Îºê¸¦ ÇÕ¼ºÇÏ¿© »ì¾ÆÀÖ´Â ¼¼Æ÷³»¿¡¼ ÇÁ·ÎºêÀÇ ±¤Ä£È¹ÝÀÀ(Photoaffinity labeling) ¹× Ŭ¸¯¹ÝÀÀ(click reaction)À¸·Î ºÐÀÚÇ¥Àû/Çü±¤¹°Áú/ÄɹÌÄÃÇÁ·Îºê º¹ÇÕü¸¦ ¸¸µé°í Àü±â¿µµ¿À¸·Î ºÐ¸®ÇÑ ÈÄ ´Ü¹éÁúü ºÐ¼®À» °ÅÃÄ MDH2°¡ LW6ÀÇ ºÐÀÚÇ¥ÀûÀÓÀ» È®ÀÎÇÏ¿´À½.
HIF-1 ÀúÇØÁ¦ LW6°¡ ¹ÌÅäÄܵ帮¾Æ È¿¼Ò ¸»»ê Å»¼ö¼ÒÈ¿¼Ò 2(MDH2)¿Í °áÇÕÀ» ÇÏ°Ô µÇ¸é ¹ÌÅäÄܵ帮¾Æ È£Èí´É·ÂÀÌ °¨¼ÒµÇ°í ¼¼Æ÷ ³» »ê¼ÒºÐ¾ÐÀÌ Áõ°¡µÇ¾î HIF-1ÀÇ ºÐÇØ°¡ ÃËÁøµÊÀ» ±Ô¸íÇÏ¿´À½.
¿ì¼ö³í¹®
Stability of the cancer target DDIAS is regulated by the CHIP/HSP70 pathway in lung cancer cells.
Cell Death Dis. 8(1):e2554.
Mi Sun Won (Corresponding)
The novel hypoxia-inducible factor-1¥á inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth.
Cell Death Dis. 8(6):e2843.
Mi Sun Won (Co-corresponding)
DNA methylation : an epigenetic mark of cellular memory.
Exp Mol Med. 49(4):e322.
Mirang Kim (First)
Methyl 3-(3-(4-(2,4,4-trimethylpentan-2-yl)phenoxy)-propanamido)benzoate as a novel and dual malate dehydrogenase (MDH) 1/2 inhibitor targeting cancer metabolism.
J Med Chem. 60(20):8631-8646.
Mi Sun Won (Co-corresponding)